Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

PHASE I/II CLINICAL TRIAL OF SYS6062 FOR THE TREATMENT OF ADVANCED SOLID TUMOURS OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA

The Board of Directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the Phase I/II clinical trial of SYS6062 (the "**Product**") developed by the Group for the treatment of advanced solid tumours has been officially initiated at the first centre in China.

The Product is an antibody-drug conjugate (ADC) developed by the Group targeting carcinoembryonic antigen-related cell adhesion molecule 5 ("**CEACAM5**"). Its antibody component specifically binds to the surface of tumour cells expressing CEACAM5 and is internalised into the cells. Following specific cleavage by proteases, the small-molecule toxin is released, thereby killing the tumour cells. Meanwhile, the Product can exert a bystander effect, non-specifically killing surrounding tumour cells.

The Group received the Notice of Approval for Clinical Trial of Drug issued by the National Medical Products Administration of the People's Republic of China in October 2026 and, following the approval, initiated a multi-centre, open-label, first-in-human Phase I/II clinical trial comprising dose escalation, pharmacokinetic ("**PK**") expansion and cohort expansion, aimed at evaluating the safety, tolerability, PK profile and preliminary anti-tumour efficacy of the Product in patients with advanced solid tumours.

Currently, the recruitment and screening of participants for this clinical trial are actively underway.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 5 November 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.